CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Vishal Navani(Hunter Medical Research Institute), Daniel Yick Chin Heng(University of Calgary), Darren R. Brenner(University of Calgary), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Winson Y. Cheung(University of Calgary), Sumanta K. Pal(City of Hope), Lisa Ludwig(Centre Hospitalier Régional et Universitaire de Nancy), Toni K. Choueiri(Harvard University), Chris Labaki(Beth Israel Deaconess Medical Center), Bernadett Szabados(Queen Mary University of London), Rana R. McKay(University of California San Diego), Luís Meza(City of Hope), Frede Donskov(Aarhus University Hospital), Bradley A. McGregor(Harvard University), Maxwell Otiato(University of Southern California), Andrew Schmidt(Dana-Farber Cancer Institute), Thomas Powles(National Health Service), Matthew Scott Ernst(University of Calgary), Devon J. Boyne(University of Calgary)
Cited by 5
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k